Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405061 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL4896464 | 0.90 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL5405068 | 0.90 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL7400523 | 0.89 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8201762 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL15114666 | 0.85 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL12137982 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL12027690 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL20564964 | 0.84 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL15105964 | 0.82 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7199158-B2 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20060166895-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2006-07-27 | — | — | US | disclosed |
| US-7038084-B2 | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-05-02 | — | — | US | disclosed |
| US-7026485-B2 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-7026333-B1 | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060040974-A1 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-02-23 | — | — | US | disclosed |
| US-20060020009-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-01-26 | — | — | US | disclosed |
| US-6951886-B2 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558673-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558657-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | ALDH1A1 2859/4885KMT2A 1293/4885MAPK1 3128/4885 |
| US-20060020009-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | HAT1, UBXN4, PRSS1 | ALDH1A1 3181/4885KMT2A 1060/4885MAPK1 3760/4885 |
| US-20060040974-A1 | Retroviral protease inhibitors | PREP, TMPRSS15, DNPEP | ALDH1A1 2626/4885KMT2A 599/4885MAPK1 2527/4885 |
| US-20060166895-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | ALDH1A1 2763/4885KMT2A 531/4885MAPK1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.